Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Account Payables (2016 - 2026)

Gyre Therapeutics has reported Change in Account Payables over the past 12 years, most recently at -$433000.0 for Q4 2025.

  • Quarterly Change in Account Payables fell 127.89% to -$433000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13000.0 through Dec 2025, up 105.31% year-over-year, with the annual reading at $13000.0 for FY2025, 105.31% up from the prior year.
  • Change in Account Payables was -$433000.0 for Q4 2025 at Gyre Therapeutics, down from $483000.0 in the prior quarter.
  • Over five years, Change in Account Payables peaked at $6.3 million in Q4 2022 and troughed at -$3.7 million in Q2 2022.
  • The 5-year median for Change in Account Payables is -$37000.0 (2024), against an average of $17400.0.
  • Year-over-year, Change in Account Payables plummeted 713.11% in 2021 and then surged 1625.0% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $2.6 million in 2021, then surged by 144.48% to $6.3 million in 2022, then tumbled by 105.38% to -$337000.0 in 2023, then skyrocketed by 43.62% to -$190000.0 in 2024, then crashed by 127.89% to -$433000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Account Payables are -$433000.0 (Q4 2025), $483000.0 (Q3 2025), and -$51000.0 (Q2 2025).